New research from Memorial Sloan Kettering Cancer Center (MSK) shows how BRCA2-mutant cancers rely on a previously unknown DNA repair lifeline; helps explain the effectiveness of cyclophosphamide, a drug used in bone marrow transplants; and finds small cell transformation persists despite early chemotherapy in high-risk EGFR-mutant lung cancer.
BRCA2-mutant cancers rely on a previously unknown DNA repair lifeline
A protein complex that helps fix gaps in damaged DNA turns out to provide a critical lifeline for BRCA2-deficient cancer cells — making it a potential therapeutic target, a new MSK study shows. Mutations in both the BRCA2 and BRCA1 genes are among the most well-known genetic risk factors for breast and ovarian cancers.
The research team — overseen by senior author Simon Powell, MD, PhD, Chair of MSK’s Department of Radiation Oncology — investigated how cancer cells lacking BRCA2 manage to survive despite DNA damage caused by the loss of BRCA2. The study was led by postdoctoral researcher Helen Grimsley, PhD.
BRCA2 is a key player in homologous recombination — a critical process cells use to repair broken DNA and ensure accurate genome duplication. When BRCA2 is lost, cells accumulate small gaps in their DNA. Left unfixed, these gaps can grow into serious DNA breaks and ultimately cause the cell to die.
Yet cancer cells with mutations that disable BRCA2 manage to survive. This suggests some unknown repair mechanism keeps these DNA gaps in check — and that’s exactly what the Powell Lab identified.
By comparing cancer cells with and without BRCA2, the scientists identified a protein complex called 9-1-1 — made up of RAD9A, RAD1, and HUS1 — that is essential to the survival of BRCA2-deficient cells.
The team found that when BRCA2-deficient cells lose the 9-1-1 complex, the DNA gaps spiral out of control — leading to cell death. That’s because 9-1-1 normally prevents an enzyme called EXO1 from expanding the DNA gaps until they’re too large to repair.
The scientists confirmed EXO1’s critical role in destabilizing cancer cells by removing it — showing cells that lacked both the enzyme and the 9-1-1 complex were able to survive the DNA damage caused by the loss of BRCA2.
The 9-1-1 complex, however, doesn’t just act as a brake on EXO1, the researchers found. It also actively recruits a specialized DNA repair polymerase called POL-zeta to fix the DNA gaps. When the researchers blocked the site where POL-zeta interacts with the 9-1-1 complex, the cancer cells lost their ability to repair the gaps.
Importantly, this reliance on the 9-1-1 complex is specific to BRCA2-deficient cells — those lacking BRCA1 did not show the same vulnerability.
The team’s laboratory findings were further supported by an analysis of The Cancer Genome Atlas, which found that disease-causing mutations in the BRCA2 gene and in the components of the 9-1-1 complex appear to be mutually exclusive.
“Our findings suggest that targeting the 9-1-1 complex could cause tumors with BRCA2 mutations to self-destruct by taking away this critical DNA repair mechanism that allows them to survive,” Dr. Powell says. “And this would target an entirely different DNA repair mechanism than PARP inhibitors, the current standard of care, which cancer cells can become resistant to.”
Read more in Molecular Cell.
Study helps explain why cyclophosphamide, a drug used in bone marrow transplants, is effective
Cyclophosphamide was established as a standard treatment for bone marrow transplant patients after a national phase 3 trial, performed by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), found it was more effective than the older tacrolimus-methotrexate combination at preventing graft-versus-host disease (GVHD) while also keeping cancer under control.
A follow-up study from that trial analyzed more than 2,000 samples taken from 324 patients. It revealed that cyclophosphamide works by wiping out all types of donor and patient T cells — not just targeting a specific subset of T cells, as previously assumed. But there can be side effects.
“It turns out there’s a trade-off when using this drug,” says first author and MSK leukemia specialist Susan De Wolf, MD. “Although it lowers the risk of GVHD, it also may increase the risk of infections, because the patients are left with fewer T cells to fight them off.”
Researchers also discovered a T cell “diversity bottleneck,” in which the significant reduction of T cells caused by cyclophosphamide results in a less diverse immune system for as long as two years after treatment. This diversity bottleneck can be detected as early as 14 days after transplant, offering a potential way to predict a patient’s long-term risks for both GVHD and infections, which could help doctors better tailor and improve treatments going forward.
This study illustrates the importance of collecting samples during clinical trials to answer important biological questions and help explain the clinical findings, the researchers note.
Co-senior authors of the study were Miguel-Angel Perales, MD, Chief of the Adult Bone Marrow Transplantation Service at MSK; Ami Bhatt, MD, PhD, of Stanford University; and Leslie Kean, MD, PhD, of Harvard Medical School and Boston Children’s Hospital.
Read more in Science Translational Medicine.
Small cell transformation persists despite early chemotherapy in high-risk EGFR-mutant lung cancer
About 20% of adenocarcinomas — which make up about half of all non-small cell lung cancers — carry mutations in the gene EGFR, which can be targeted with drugs like osimertinib (Tagrisso®). But in some cases, cancers treated with these drugs transform into small cell lung cancer (SCLC), a more aggressive disease that is harder to treat.
A recent study led by MSK researchers tested a strategy to prevent that transformation and investigated what makes some tumors prone to changing identity.
In an earlier MSK study spearheaded by the same team, 7 of 39 patients whose non-small cell lung cancers carried alterations in the EGFR, TP53, and RB1 genes developed SCLC. That finding helped identify a high-risk group for transformation and formed the basis of this new trial, which studied patients newly diagnosed with metastatic EGFR-positive non-small cell lung cancer with concurrent TP53/RB1 mutations. In addition to osimertinib, these patients were given platinum and etoposide chemotherapies (standard drugs for treating SCLC).
Despite the addition of chemotherapy, nearly half (5 of 11 patients) still had their cancers transform into SCLC. Survival outcomes were similar to what earlier studies reported for patients with the same tumor alterations receiving osimertinib alone. By studying patient samples alongside cell lines in the lab, the researchers uncovered important new clues about how the transformation happens.
In some tumor samples, single-cell RNA sequencing detected SCLC-like gene activity that had been missed by routine examination under a microscope. The explanation could be either the cell identity shifted earlier, or the cluster of SCLC was too small to be detected.
Scientists found that in other samples, the tumors resembled another type of lung cancer called squamous lung cancer. And in 40% of patients whose cancers transformed, the tumors acquired mutations that activate PI3K/AKT, a pathway that helps cells survive. Whether those mutations contributed to transformation remains unclear.
In lab experiments, the RB1 mutation changed how DNA was packaged in tumor cells, which may make it easier for them to change identity. Osimertinib appeared to amplify some of the changes linked to RB1 loss, suggesting that the combination of the drug and RB1 further increased the likelihood of transformation.
“These findings suggested a different approach may be needed when treating patients with these mutations,” says co-senior author Helena Yu, MD, of MSK. “It also suggests that treating the cancer as SCLC upfront is not appropriate, but that we need to instead target what is driving these changes.”
“TP53 and RB1 alterations identify patients at higher risk, but we still need better early markers to tell us which tumors are most likely to become small cell lung cancer,” says co-senior author Joseph Minhow Chan, MD, PhD, also of MSK. “Our analysis suggests that loss of RB1 function can set changes in tumor cell identity in motion, but we now need to understand how targeted therapy and chemotherapy shape those changes even further.”
Read more in Science Translational Medicine.